We met with Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori) at ESMO 2019 to discuss the 3-year follow-up results from the phase III KEYNOTE-045 trial: Pembrolizumab Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (NCT02256436).
1. What are the limitations of the current standard of care for the second-line treatment of patients with recurrent urothelial cancer? (0:05)
2. Could you tell us a little about the aims and design of the KEYNOTE-045 study? (3:44)
3. What is the role of programmed death-ligand 1 (PD-L1) expression in predicting response? (6:02)
4. What future studies of pembrolizumab in urothelial cancer are planned? (7:36)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Andrea Necchi has received honoraria from Roche, Merck, AstraZeneca, Janssen, and Foundation Medicine; has served as a consultant/advisor for Merck Sharp & Dohme, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol-Myers Squibb, and Rainier Therapeutics; has received institutional research funding from Merck Sharp & Dohme and AstraZeneca; has received travel expenses from Roche, Merck Sharp & Dohme, AstraZeneca, Janssen, and Rainier Therapeutics; and has an immediate family member who has other relationships with Bayer.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Genitourinary Cancer
Axel Merseburger: International Men’s Day and EU Prostate Cancer Day and the Importance of Raising Awareness of Men’s Health and Well-being
Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), gives his thoughts on the importance of International Men’s Day and EU Prostate Cancer Day in raising awareness of men’s health and well-being. Question International Men’s Day and EU Prostate Cancer Day are both held in November. What is the importance of raising awareness of male […]
Axel S Merseburger, ESMO 2021: Highlights and Key Data in Advanced Prostate Cancer
touchONCOLOGY joins our Editor-in-Chief Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), to discuss the key data presented at the ESMO Congress 2021 in the field of advanced prostate cancer and the significant impact these advances have on clinical practice. Questions 1. What were the hottest topics and exciting new research from the ESMO […]
Neeraj Agarwal, ESMO 2021: Results of Expanded Cohort 6 of the COSMIC-021 Study
touchONCOLOGY joins Professor Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA) at ESMO 2021 to discuss the much-anticipated results of the COSMIC-021 study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. Questions 1. What is the rationale for the combined use of cabozantinib and atezolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!